# Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

> **NCT01282762** · — · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 147 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **BIOLOGICAL:** HEPLISAV
- **BIOLOGICAL:** Engerix-B

## Key facts

- **NCT ID:** NCT01282762
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282762, "Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01282762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*